1439
document
[ Efficacy of combination with granisetron and methylprednisolone for nausea , vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia -- a randomized comparative trial between granisetron alone and granisetron plus methylprednisolone ] . The prevention of nausea , vomiting and appetite loss induced by remission induction chemotherapy for acute myeloid leukemia was compared by randomization between granisetron alone and combination with granisetron plus methylprednisolone . Granisetron was administered at 40 micrograms/kg during chemotherapy , and methylprednisolone was administered concomitantly at 125 mg/body for 3 days or more in the combination group . The single and combination groups comprised 14 and 13 patients , respectively , and there was no significant difference between the background of both groups . To evaluate the effect they were scored according to 4 grades , and evaluated every 24 hours from the start of chemotherapy to 5 days after its completion . The complete inhibition rate of vomiting was as high as 71.4 % and 92.3 % in the single and combination groups , respectively , showing no significant difference . The grade of vomiting was mild in both groups . Nausea was noted in 71.4 % and 46.2 % , respectively , and the inhibitory effect tended to be higher in the combination group . Appetite loss developed in 92.9 % and 41.7 % , respectively , and the prevention effect was clearly higher in the combination group . The prevention effects on nausea 7 , 8 and 10 days after the start of chemotherapy , on appetite loss 2-10 days after it , and 2-5 days after its completion , were higher in the combination group . Granisetron revealed an excellent inhibitory effect on vomiting induced by remission induction chemotherapy for acute myeloid leukemia , but combination with granisetron and methylprednisolone was considered useful for nausea in the latter half of the treatment period and for appetite loss during the whole period .
1440
Intervention_Pharmacological
granisetron and methylprednisolone
1441
Intervention_Pharmacological
granisetron alone
1442
Intervention_Pharmacological
granisetron plus methylprednisolone
1443
Intervention_Pharmacological
granisetron alone
1444
Intervention_Pharmacological
granisetron
1445
Intervention_Pharmacological
methylprednisolone
1446
Intervention_Pharmacological
Granisetron
1447
Intervention_Pharmacological
40 micrograms/kg during chemotherapy
1448
Intervention_Pharmacological
methylprednisolone
1449
Intervention_Pharmacological
Granisetron
1450
Intervention_Pharmacological
granisetron and methylprednisolone
1451
Outcome_Physical
nausea
1452
Outcome_Physical
vomiting
1453
Outcome_Physical
appetite loss
1454
Outcome_Physical
nausea
1455
Outcome_Physical
vomiting
1456
Outcome_Physical
appetite loss
1457
Outcome_Physical
complete inhibition rate of vomiting
1458
Outcome_Physical
grade of vomiting
1459
Outcome_Physical
Nausea
1460
Outcome_Physical
Appetite loss
1461
Outcome_Physical
nausea
1462
Outcome_Physical
on appetite loss
1463
Outcome_Physical
inhibitory effect on vomiting
1464
Outcome_Physical
nausea
1465
Outcome_Physical
appetite loss
1466
Participant_Condition
nausea , vomiting and appetite loss in remission induction chemotherapy of acute myeloid leukemia -- a
1467
Participant_Condition
acute myeloid leukemia